» Articles » PMID: 38601172

Adrenal Infarction with Latent Myelodysplastic/myeloproliferative Neoplasm, Unclassifiable with V617F Mutation

Overview
Journal Clin Case Rep
Date 2024 Apr 11
PMID 38601172
Authors
Affiliations
Soon will be listed here.
Abstract

Key Clinical Message: Hematopoietic neoplasms can cause adrenal infarction. In cases of thrombosis occurring at uncommon sites, it is necessary to consider evaluating for the V617F mutation, even in the absence of notable abnormalities in blood counts.

Abstract: Adrenal infarction, a rare ailment, has been sporadically linked to hematopoietic neoplasms. A 46-year-old male encountered left adrenal infarction, which coincided with a progressive rise in platelet counts. Subsequent diagnosis revealed myelodysplastic/myeloproliferative neoplasm-unclassifiable, featuring a V617F mutation. Simultaneously, the patient manifested multiple arteriovenous thromboses, necessitating treatment with edoxaban, aspirin, and hydroxyurea. Following thrombosis resolution, he was transferred to a transplantation center. This report delves into the thrombogenicity linked to the V617F mutation, while also examining documented instances of adrenal infarction in myeloid neoplasms. We should consider evaluating for V617F mutation even in cases of thrombosis at unusual sites, including adrenal infarction, even if there are no considerable abnormalities in blood counts.

Citing Articles

Adrenal infarction with latent myelodysplastic/myeloproliferative neoplasm, unclassifiable with V617F mutation.

Yasuda S, Chiba M, Nishitani R, Watanabe T Clin Case Rep. 2024; 12(4):e8729.

PMID: 38601172 PMC: 11004262. DOI: 10.1002/ccr3.8729.

References
1.
Luque Paz D, Kralovics R, Skoda R . Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood. 2022; 141(16):1909-1921. PMC: 10646774. DOI: 10.1182/blood.2022017578. View

2.
Yasuda S, Chiba M, Nishitani R, Watanabe T . Adrenal infarction with latent myelodysplastic/myeloproliferative neoplasm, unclassifiable with V617F mutation. Clin Case Rep. 2024; 12(4):e8729. PMC: 11004262. DOI: 10.1002/ccr3.8729. View

3.
Gupta N, Edelmann B, Schnoeder T, Saalfeld F, Wolleschak D, Kliche S . JAK2-V617F activates β1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1. Leukemia. 2017; 31(5):1223-1226. PMC: 5420787. DOI: 10.1038/leu.2017.26. View

4.
Agha A, Bateman H, Sterrett A, Valeriano-Marcet J . Myelodysplasia and malignancy-associated vasculitis. Curr Rheumatol Rep. 2012; 14(6):526-31. DOI: 10.1007/s11926-012-0281-3. View

5.
Wang Q, Dai H, Liu D, Xie J, Yao H, Ding Z . Efficacy of ruxolitinib in a patient with myelodysplastic/myeloproliferative neoplasm unclassifiable and co-mutated JAK2, SF3B1 and TP53. Leuk Res Rep. 2020; 14:100229. PMC: 7645062. DOI: 10.1016/j.lrr.2020.100229. View